Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Targovax ASA ( (GB:0RIS) ) has issued an announcement.
Circio Holding ASA has announced that key insiders have participated in its ongoing rights issue, reinforcing internal support for the company’s current capital-raising effort. Chief Scientific Officer Victor Levitsky has exercised 32,698 subscription rights and additionally subscribed for 217,302 offer shares without rights, for a total of 250,000 new shares at NOK 1.00 per share, while Sølen AS, a company closely associated with board member Thomas Falck, has exercised 65,164 subscription rights and subscribed for an additional 134,836 offer shares without rights, totaling 200,000 new shares on the same terms. Both parties will be allocated an equivalent number of warrants without extra consideration, subject to board approval and completion of the rights issue, signaling confidence from management and board-level stakeholders in the company’s financing plan and future prospects, and complying with mandatory insider trading disclosure rules under EU and Norwegian law.
More about Targovax ASA
Circio Holding ASA is a Norway-based listed company active in the biotechnology and life sciences sector, with its shares traded on the Oslo market. The company operates under Norwegian securities regulations, including the EU Market Abuse Regulation and the Norwegian Securities Trading Act, and is subject to related disclosure requirements regarding insider transactions and capital market activities.
Average Trading Volume: 3,882,459
Current Market Cap: NOK207.2M
For an in-depth examination of 0RIS stock, go to TipRanks’ Overview page.